Baxalta Announces Secondary Offering of Common Stock


BANNOCKBURN, Ill.--(BUSINESS WIRE)-- Baxalta Incorporated (NYSE: BXLT) announced today the commencement of an underwritten public offering of approximately $2.34 billion of its common stock previously issued to and currently owned by Baxter International Inc. (“Baxter”), Baxalta’s former parent company. Baxalta is not selling any shares and will not receive any proceeds from the sale of the shares in the offering or the debt-for-equity exchange (as described below).

Prior to the closing of the offering, Baxter will exchange the shares of Baxalta common stock to be sold in the offering for indebtedness of Baxter currently held by J.P. Morgan Securities LLC, BofA Merrill Lynch, Credit Suisse Securities (USA) LLC and UBS Securities LLC (collectively, the “Selling Stockholders”). Following the debt-for-equity exchange, Baxter’s retained ownership stake in Baxalta will be reduced from approximately 13.8% to 5.1% (based on the Baxalta closing stock price on March 14, 2016). The Selling Stockholders will then sell these shares of Baxalta common stock to the underwriters in connection with the public offering.

J.P. Morgan, BofA Merrill Lynch, Credit Suisse and UBS Investment Bank are acting as the underwriters for the offering.

The offering will be made only by means of a prospectus. A copy of the preliminary prospectus related to the offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by calling toll-free at (866) 803-9204; BofA Merrill Lynch, c/o 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or by email at; Credit Suisse Securities (USA) LLC, Prospectus Department, One Madison Avenue, New York, NY 10010, or by calling toll-free at (800) 221-1037 or by email at; or UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, or by calling toll-free at (888) 827-7275. You may also obtain a copy of the preliminary prospectus, without charge, by visiting the SEC’s website at

A registration statement on Form S-1 relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Baxalta

Baxalta Incorporated (NYSE: BXLT) is a global biopharmaceutical company developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. Launched in 2015 following its separation from Baxter, Baxalta’s therapies are available in more than 100 countries.

Source: Baxalta Incorporated

Baxalta Media Relations

Geoffrey Mogilner, 1-224-940-8619


Baxalta Investor Relations

Mary Kay Ladone, 1-224-940-3371


Lorna Williams, 1-224-940-3511

Baxalta is now a part of Shire Lean more

You may contact Baxalta’s Corporate Communications team at:

Baxalta Media Hotline: